Michael J. Farrell - Apr 7, 2025 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Stock symbol
RMD
Transactions as of
Apr 7, 2025
Transactions value $
-$866,664
Form type
4
Date filed
4/9/2025, 10:52 AM
Previous filing
Apr 2, 2025
Next filing
May 9, 2025
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -8.01K -12.5% $0.00 56.1K Apr 7, 2025 ResMed Common Stock 8.01K $101.64 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $200.18 - $218.54. The price reported above reflects the weighted average sale price.
F3 Represents date options first become exercisable. Options vest 1/3 per year.